Novartis

Novartis remibrutinib cuts MS relapse rates in dual Phase III trials

Novartis announced positive topline results from its Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib, an oral BTK inhibitor, in relapsing multiple sclerosis. Across approximately 2,000 patients, remibrutinib demonstrated superiority over teriflunomide in reducing annualized relapse rates, cutting MRI lesions, and achieving clinically meaningful delays in disability progression. The drug showed no liver safety signal across a clinical program of more than 4,500 participants, and Novartis plans to submit for global regulatory approval. This positions remibrutinib as a potential high-efficacy oral alternative in a disease affecting nearly 3 million people worldwide.